Feb. 7, 2007 — Cardium Therapeutics and its operating unit InnerCool Therapies have announced they will launch two next-generation systems for patient temperature modulation. Both solutions are expected to be cleared and commercially available within the next two quarters, the companies report.
The rapidly advancing field of patient modulation focuses on improving outcomes following major medical events such as stroke, cardiac arrest and heart attack, as well as on the management of patients experiencing trauma or fever.
Internal temperature modulation is designed to rapidly cool patients from within their bodies in order to reduce cell death and damage caused by acute ischemic events such as cardiac arrest, heart attack or stroke, and to prevent or reduce associated injuries such as adverse neurologic outcomes. InnerCool's new internal temperature modulation system, which will include an enhanced console and disposable catheter, provides rapid re-warming of patients following surgery or other medical procedures, and for the potential warming of patients such as trauma victims.
In addition, InnerCool's new external temperature modulation system, which will include a console and disposable pads, is designed to provide a complementary tool for use in less-acute patients and in clinical settings that do not require very rapid cooling or re-warming, or which are best suited to prolonged temperature management.
The American Heart Association (AHA) and the International Liaison Committee on Resuscitation (ILCOR) have issued guidelines recommending that cardiac arrest victims be treated with induced hypothermia.
InnerCool's current internal temperature modulation system, which is marketed as the Celsius Control System, is being used to induce, maintain and reverse hypothermia in neurosurgical patients, both in surgery and in recovery or intensive care; the company also has received FDA clearance for use in cardiac patients (in order to achieve or maintain normal body temperatures during surgery and in recovery/intensive care), and as an adjunctive treatment for fever control in patients with cerebral infarction and intracerebral hemorrhage.
For more information visit www.innercool.com.